Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Ovarian Cancer

Ovarian Cancer Cells That Survive Chemotherapy Send a Sugar Signal That Helps Neighbors Break Away

Wistar researchers found that chemo-surviving ovarian cancer cells release fructose that loosens neighboring cells. The work is preclinical and has not been tested in patients.

Medical Daily

Cancer patient becomes world’s first to receive ‘landmark’ treatment

Tracy Tomlinson, 58, was given the drug at the Christie NHS Foundation Trust in Manchester as part of a clinical trial evaluating a new type of treatment for several types of cancer

The Independent UK

Woman becomes first to receive pioneering new cancer therapy

Tracy Tomlinson was diagnosed with ovarian cancer which had spread shortly before Christmas 2020.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson seeks to end decade-long talc litigation with $5.5 billion settlement

Johnson & Johnson has struck a substantial deal worth more than five billion dollars, aimed at settling numerous lawsuits that allege cancer linked to its talc products. Following an ineffective bankruptcy resolution attempt, this latest agreement will facilitate quicker claims disbursement while keeping the door open for others who develop…

The Economic Times

Johnson & Johnson Pays $5.5B Over Baby Powder Cancer Claims; Wall Street Rewards It Anyway

Johnson & Johnson's $5.5B talc settlement impacts ovarian cancer claims and stock performance. Learn about the legal outcomes, unresolved issues, and future implications for claimants and investors.

International Business Times UK

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer

The Independent UK

J&J reaches sweeping talc product settlement

NEW YORK - ‌Johnson & Johnson has announced that it will pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer, in a landmark deal that could end a contentious legal battle that has dogged the company…

Bangkok Post

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson reaches $5.5 bn talc settlement that could end decade of litigation

Johnson & Johnson will pay an estimated $5.5 billion to resolve talc product lawsuits. This landmark deal covers approximately seventy-six thousand claims alleging cancer causation. The company previously settled most claims involving asbestos and mesothelioma litigation. Johnson & Johnson expects to pay $3 billion in 2027 and further payments in…

The Economic Times

Ads call ovarian cancer a ‘silent killer’. But does urging women to undergo early detection testing do more harm than good?

Website offering blood check is aimed at people with a higher risk of disease – and false positives can create fear

The Guardian - AU

Tennis legend Chris Evert says her ovarian cancer has returned: ‘It’s relentless, but I’ll stay optimistic’

The American, 71, is a former world No 1 and 18-time grand-slam champion

The Independent UK

Ovarian cancer drug approved for NHS use will prolong lives

A drug that can treat chemotherapy-resistant ovarian cancer has just been approved for use on the NHS in England. Mirvetuximab soravtansine (also known as Elahere) is the first new drug to be approved for hard-to-treat ovarian cancer in over 20 years.

The Conversation

Oxford University and Moderna launch trials of vaccine that could prevent cancer

The jab targets patients with Lynch syndrome, who are at high risk of colorectal and ovarian cancer

The Independent UK

Johnson & Johnson beats lawsuit alleging that talc caused three women's cancer

A Los Angeles jury ruled in favor of Johnson & Johnson, finding the company not negligent in a lawsuit alleging its talc products caused ovarian cancer. This verdict comes as J&J faces thousands of similar claims, having previously won some cases and lost others, and having discontinued talc-based baby powder…

The Economic Times

‘Landmark’ ovarian cancer treatment approved for NHS use

IN FULL

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

Evening Standard

'Significant breakthrough' as new ovarian cancer treatment approved for NHS use

A former NHS worker from north London who is taking the drug says the new treatment has let her ‘get on with my life’

The Independent UK

Breakthrough ovarian cancer drug that extends lives to be free on NHS for first time

Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the treatment for NHS use

MarketBeat

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development. John Oyler, BeOne’s co-founder, chairman and chief

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

She fainted in school from period pain for years; now the 27-year-old fights stage 4 cancer alone after losing her father, with no siblings by her side

Radhika Sapra endured years of dismissed menstrual pain, only to be diagnosed with stage 4 ovarian cancer at 22. Now 27, she battles the disease and financial hardship, a journey marked by childhood abuse and abandonment. She lost her father in 2022 and has no siblings. Despite immense challenges, she…

MarketBeat

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MyLifeXP

7 Early Cancer Signs Most People Ignore

Cancer often begins quietly, making its early signs easy to overlook. A little fatigue, unusual swelling, constant bloating, or pain that refuses to fade may seem like ordinary health issues at first. That is what makes early cancer symptoms so dangerous they often appear normal until they slowly become serious.…

The Independent UK

Researchers warn of key new driver of 11 cancers in under-50s – and it’s not smoking or poor diet

A new study has found that 11 types of cancer are on the rise in the 20 to 49-year-old age group

The Independent UK

Drug for rare disease could be used to extend lives of ovarian cancer patients, study finds

Patients with a certain type of ovarian cancer could benefit by taking a drug for Cushing’s syndrome

The Guardian - UK

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows

Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases

The Independent UK

Landmark tumour mapping research could boost targeted breast and ovarian cancer therapies

The researchers said the findings indicate many more patients may benefit from precision therapies

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Oxford

the American Cancer Society

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.